A new generation of chimeric antigen receptor (CAR) T-cell therapies with advanced functions could hold the answer to improved safety and efficacy for these effective but potentially dangerous cancer therapies, shows research led by Boston University. The scientists showed it is possible to add ‘on’ or ‘off’ switches to CAR T cells, which can be activated using oral drugs with a known safety profile.

Scientists have discovered a new antibiotic called evybactin that is able to selectively target Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB) lung infections. As described in Nature Chemical Biology on Aug. 22, 2022. the work is still at an early stage and requires further validation. But, if successful in clinical trials, evybactin could form part of a new group of specific antibiotics designed to target TB.

Research carried out by a team at St. Jude Children's Research Hospital in Memphis highlights the importance of carefully assessing the mouse model you plan to use before starting preclinical medical research.

Research led by the University of Texas Southwestern Medical Center reveals a protein signature that can reliably predict whether patients with nonalcoholic fatty liver disease (NAFLD) are likely to develop hepatocellular carcinoma, the most common form of liver cancer.